0809 ET - RBC says that while Life Sciences remains automation company ATS's primary focus, its radiopharma sub-segment, which covers diagnostics, therapeutics and radioisotopes, is emerging as an important growth driver. Analyst Sabahat Khan says in a note that ATS has historically been involved with diagnostics, and that isotope production automation is a near-term opportunity. Longer-term, Khan sees pharmaceutical automation for approved therapies--such as smaller batch, decentralized production requiring intense automation given the therapies are hazardous to operators--as a "potentially larger opportunity."